Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of lutetium (177Lu) vipivotide tetraxetan in adult participants with prostate cancer
jRCT2031250705Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Novartis. Primary endpoints: Long-term adverse events and serious adverse events and Changes in laboratory values. Started Jun 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250705.